FREQ News and Press, Frequency Therapeutics Inc. From 11/08/22

Frequency Therapeutics press release ( NASDAQ: FREQ ): Q3 GAAP EPS of -$0.55. Cash, cash equivalents and marketable securities as of September 30, 2022, were $99.3 million Based on current plans and assumptions, the Company believes its existing cash, cash equivalents ...

Enrollment Completed for Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss; Readout Expected in Q1 2023 Company on Track for Q4 Clinical Trial Start of its Second Hearing Restoration Program, FX-345 Multiple Sclerosis Remyelination Program Candid...

Frequency Therapeutics ( NASDAQ: FREQ ) added ~16% Wednesday after Baird initiated coverage on the clinical-stage biotech with an Outperform recommendation noting an upcoming mid-stage readout for its lead asset FX-322. The experimental small molecule drug is currently...

Study of Therapeutic to Restore Hearing Aims to Show Speech Perception Improvements in Individuals with Noise-Induced or Permanent Sudden Sensorineural Hearing Loss Company Aligned with FDA on Speech Perception Primary Endpoint Readout Expected in Q1 2023 Fre...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that members of its management team will participate in investor and medical...

Frequency Therapeutics press release ( NASDAQ: FREQ ): Q2 GAAP EPS of -$0.61. Cash, cash equivalents and marketable securities as of June 30, 2022, were $111.0 million (excluding restricted cash). For further details see: Frequency Therapeutics GAAP EPS of -$0.61...

Q1 2023 Readout Planned for FX-322-208 Phase 2b Sensorineural Hearing Loss Study, with Enrollment Completion Anticipated in Q3 Q4 Enrollment Start Planned for Phase 1b Study of Second Hearing Restoration Program, FX-345 Company Advances Remyelination in Multiple Sclero...

Most of us know someone affected by hearing loss, but we may not fully appreciate the hardships that lack of hearing can bring. Hearing loss can lead to isolation, frustration, and a debilitating ringing in the ears known as tinnitus. It is also closely correlated with dementia. Read More >...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Scientific Officer Dr. Christopher Loose will presen...

Buying Penny Stocks on May 10th? Here’s What You Need to Know After another topsy turvy day of trading penny stocks and blue chips, there is a lot for investors to know. In the past few weeks, trading has been extremely difficult as a result of high inflation, rising interest rat...